A comparison of dextro-amphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction.
In a double-blind trial of placebo, dextro-amphetamine, racemic-amphetamine, and methylphenidate, each used for a week, in 48 children with the diagnosis of Minimal Brain Dysfunction or Hyperkinetic Syndrome, it was found that although on the average dextro-amphetamine as well as methylphenidate was significantly superior to racemic-amphetamine, with side effects about the same, in some cases racemic-amphetamine was superior to both dextro-amphetamine and methylphenidate. In 20 cases, improvement was about the same for both the dextro and racemic forms; of these 20, side effects were absent for both in 10 patients; dextro-amphetamine showed fewer side effects in 3 patients, and racemic-amphetamine showed fewer side effects in 7 patients. In 20 other patients, dextro-amphetamine resulted in greater clinical improvement than racemic-amphetamine, while in 7 cases the reverse was true.
D000293:Adolescent; D000367:Age Factors; D000661:Amphetamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003913:Dextroamphetamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy*; D007206:Individuality; D008774:Methylphenidate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D008774:Methylphenidate; D000661:Amphetamine; D003913:Dextroamphetamine